20 evolution "https:" "https:" "https:" "https:" "https:" "https:" positions at King's College London
Sort by
Refine Your Search
-
science. The successful candidate will be appointed to the Cybersecurity (CSY) group, where our work on cryptography sits, and will have the opportunity to contribute to cross-cutting hubs (see https://www.kcl.ac.uk
-
the Heat and Fire Lab (https://heatandfire.github.io/ ) in the Department of Engineering at King’s College London. About the role We are looking to appoint a full-time (1.0 FTE) Research Associate to work
-
. The project will involve the development of theoretical techniques for exploring the quantum many-body physics of ultracold polar molecules. The candidate will be embedded in an active research environment
-
funded by EPSRC. The project will be led by Carmine Ventre, https://www.kcl.ac.uk/people/carmine-ventre . The role holder will join the Distributed AI group in the Department of Informatics at King’s
-
Professor Nicola Fear, CBE. For more information, please see https://kcmhr.org KCMHR in partnership with RAND Europe runs the Centre for Evidence for the Armed Forces Community, funded by the Forces in Mind
-
members and 110 PhD students, and offers an exceptional multidisciplinary environment for cutting-edge cardiovascular and metabolic research. Learn more about our school (https://www.kcl.ac.uk/scms ) Our
-
Science & Public Policy, the SGA offers on-campus programmes across a number of departments such as the Departments of Geography, International Development, and Global Health & Social Medicine. Join us in
-
. The project will involve the development of theoretical techniques for exploring the quantum many-body physics of ultracold polar molecules. The candidate will be embedded in an active research environment
-
more than 400 staff members and 110 PhD students, and offers an exceptional multidisciplinary environment for cutting-edge cardiovascular and metabolic research. Learn more about our school (https
-
. This role will oversee a Phase 2/3 multi-arm, multi-stage (MAMS) trial evaluating the safety and efficacy of repurposed biosimilars and biologics in adults with epidermolysis bullosa (EB). https